672 completed. 672 Phase 3, 35 Phase 2.
By phase and status
Follow AstraZeneca: new trials by email
Trials (filtered) newest first · largest first
All 672 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
ICS-LABA, benralizumab, Placebo for Benralizumab - Eosinophilic Asthma | Phase 3 | Completed | 130 | 2025-03-28 | 2026-10-16 |
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFA - Asthma | Phase 3 | Completed | 424 | 2024-07-22 | 2026-09-08 |
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Baxdrostat, Placebo - Uncontrolled Hypertension, Resistant Hypertension | Phase 3 | Completed | 326 | 2024-04-08 | 2026-04-21 |
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
Baxdrostat, Placebo - Resistant Hypertension | Phase 3 | Completed | 218 | 2024-03-01 | 2026-08-06 |
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
Benralizumab - Severe Eosinophilic Asthma | Phase 3 | Completed | 504 | 2024-02-28 | 2026-09-03 |
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD
BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Completed | 297 | 2024-01-11 | 2025-08-27 |
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
Budesonide/albuterol metered-dose inhaler 160/180 μg, Placebo metered-dose inhaler - Asthma, Exercise-Induced | Phase 3 | Completed | 64 | 2023-12-22 | 2025-08-27 |
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
Baxdrostat, Placebo - Uncontrolled Hypertension, Resistant Hypertension | Phase 3 | Completed | 796 | 2023-11-22 | 2026-11-03 |
A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).
Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | 171 | 2023-10-24 | 2026-03-05 |
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Placebo, Tozorakimab - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | 1454 | 2023-09-22 | 2026-07-24 |
A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab
Nirsevimab - Respiratory Syncytial Virus Infections | Phase 3 | Completed | 33 | 2023-07-27 | 2026-04-16 |
A Phase 3b, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as 1L Treatment for the Chinese Patients With Unresectable Biliary Tract Cancers (BTC)
durvalumab - Biliary Tract Cancers | Phase 3 | Completed | 116 | 2023-07-21 | 2025-04-22 |
Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
Eculizumab - Atypical Hemolytic Uremic | Phase 3 | Completed | 25 | 2023-07-14 | 2025-12-08 |
Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
Eculizumab - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Completed | 25 | 2023-07-05 | 2026-06-01 |
Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants
HFO-1234ze(E), HFA-134a - Mucociliary Clearance | Phase 3 | Completed | 35 | 2023-06-14 | 2026-02-25 |
Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma
HFA MDI, HFO MDI - Asthma | Phase 3 | Completed | 52 | 2023-05-02 | 2026-02-06 |
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Tozorakimab 1, Tozorakimab 2, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | 1713 | 2023-03-06 | 2026-06-25 |
A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)
BFF MDI 160/9.6 μg BID (320/19.2μg/day), BD MDI 160 μg BID (320 μg/day) - Asthma | Phase 3 | Completed | 374 | 2023-02-27 | 2026-01-28 |
Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)
AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort) - COVID-19, SARS-CoV-2 | Phase 2 / Phase 3 | Completed | 3882 | 2022-12-16 | 2026-06-18 |
PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction
PT027, PT007 - Asthma | Phase 3 | Completed | 190 | 2022-09-28 | 2026-01-27 |
Showing 20 of 672. Sign in to see all of them.
Conditions studied
Asthma (109) · Diabetes Mellitus, Type 2 (101) · Pulmonary Disease, Chronic Obstructive (55) · Diabetes Mellitus (51) · Breast Neoplasms (32) · Hypercholesterolemia (22) · Bipolar Disorder (18) · Schizophrenia (18) · Hypertension (16) · Lung Diseases (16) · Respiratory Tract Diseases (16) · Depression (15) · Lung Diseases, Obstructive (15) · Bronchial Diseases (14) · Depressive Disorder, Major (14)
Interventions
dapagliflozin (51) · Budesonide (47) · Quetiapine Fumarate (46) · Rosuvastatin Calcium (42) · Budesonide, Formoterol Fumarate Drug Combination (41) · Esomeprazole (38) · Exenatide (38) · saxagliptin (33) · Metformin (30) · Formoterol Fumarate (29) · ciclesonide (29) · benralizumab (22) · Anastrozole (20) · Roflumilast (20) · aclidinium bromide (18)
Countries
United States (327) · Canada (204) · Germany (181) · Poland (152) · United Kingdom (145) · Spain (144) · Hungary (136) · France (128) · Russia (125) · Mexico (121) · Italy (120) · South Korea (118) · Japan (111) · Australia (110) · Belgium (105)
Top investigators
Catherine Bonuccelli (11) · Esther Garcia, MD (11) · Russell Esterline (11) · James Malone, MD (8) · Lisa Porter, MD (7) · Deborah Price, MSc (6) · Paula Fernstrom (5)
Results publications
PMID 38770818, PMID 22236356, PMID 22913891, PMID 26894924, PMID 27402391, PMID 24816198, PMID 32306296, PMID 23748506, PMID 24067192, PMID 24175720, PMID 26474010, PMID 27033025, PMID 27160944, PMID 36005278, PMID 42551404, PMID 20102307, PMID 23485955, PMID 23497790, PMID 23795975, PMID 28419462, PMID 33368935, PMID 34473343, PMID 35713300, PMID 36472162, PMID 38682786, PMID 42476723, PMID 19196892, PMID 19451554, PMID 21225239, PMID 21309844, PMID 21680990, PMID 22129214, PMID 22143997, PMID 22329608, PMID 23522121, PMID 23673347, PMID 24394383, PMID 25326006, PMID 25414932, PMID 25670896, PMID 26498386, PMID 26612545, PMID 27342744, PMID 27461213, PMID 28074135, PMID 29331313, PMID 29431256, PMID 29536781, PMID 30802500, PMID 31364269
NIH funding
2014 (11), 2018 (10), 2023 (9), 2019 (7), 2017 (6), 2016 (5), 2005 (4), 2015 (4), 2009 (2), 2025 (2), 2004 (1), 2008 (1)